Inhibitors of Hsp90 kill tumor cells by synergistically interfering with multiple signaling pathways (Sabbah et al., 2020), and the findings of numerous studies have indicated that these HSP90 inhibitors are therapeutically effective against a range of tumors types, including leukemias, colon cancer, melanomas, breast cancer, ovarian cancer, and prostate cancer. This evidence concerns the gene HSP90AB1 and leukemia.